


글로벌 제약사 파이프라인 분석

- Novartis -

2022. 06.


국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Oncology	67	42%
Immunology	35	22%
Respiratory & Allergy	11	7%
Neuroscience	10	6%
Infectious	9	6%
Hematology	7	4%
Ophthalmology	7	4%
Cardiovascular	5	3%
Metabolic	4	2.5%
Renal	4	2.5%
Musculoskeletal	1	1%
합계	160개	100%

• 물질별 파이프라인



물질	개수	비중
Small molecules	61	38%
Antibody	51	32%
N/A(Not Applicable)	22	14%
Cell Therapy	7	4%
Peptide	5	3%
RNA	4	2%
Protein	4	3%
Gene therapy	3	2%
Other	2	1%
ADC	1	1%
합계	160개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 3	KJX839	Leqvio	inclisiran	Secondary prevention of cardiovascular events in patients with elevated levels of LDLC (CVRR-LDLC)	RNA	PCSK9	siRNA (regulation of LDL-C)	Mono	Anylam
2	Cardiovascular	Phase 3	KJX839	Leqvio	inclisiran	Pediatric hyperlipidemia	RNA	PCSK9	siRNA (regulation of LDL-C)	Mono	Anylam
3	Cardiovascular	Phase 3	LCZ696	Entresto	sacubitril+ valsartan	Congestive heart failure, pediatrics	Small molecules	AT1, Nprilysin	Angiotensin receptor/ neprilysin inhibitor	Mono	-
4	Cardiovascular	Phase 3	TQJ230		pelacarsen	Secondary prevention of cardiovascular events in patients with elevated levels of Lipoprotein(a) (CVRR-Lp(a))	RNA	Lp(a)	Antisense therapy	Mono	Ionis Pharmaceuticals
5	Cardiovascular	Phase 2	HSY244			Atrial fibrillation	N/A	N/A	N/A	Mono	-
6	Hematology	Phase 3	LNP023		iptacopan	Atypical Hemolytic Uremic Syndrome	Small molecules	Complement factor B (CFB)	CFB inhibitor	Mono	-
7	Hematology	Phase 3	LNP023		iptacopan	Paroxysmal nocturnal hemoglobinuria	Small molecules	Complement factor B (CFB)	CFB inhibitor	Mono	-
8	Hematology	Phase 2	LNP023		iptacopan	Autoimmune cytopenias	Small molecules	Complement factor B (CFB)	CFB inhibitor	Mono	-
9	Hematology	Phase 2	SEG101	Adakveo	crizanlizumab	Ped sickle cell anemia with crisis, pediatrics	Antibody	P-selectin (SELP, CD62P)	P-selectin inhibitor	Mono	-
10	Hematology	Phase 2	INC424	Jakavi	ruxolitinib	Myelofibrosis (combo)	Small molecules	JAK1/JAK2	JAK1/JAK2 inhibitor	Combination	Incyte Corp

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
11	Hematology	Phase 1	ADPT03			Sickle cell anemia	Cell Therapy	BCL11A	BCL11A	Mono	-
12	Hematology	Phase 1	MBG453		sabatolimab	Low risk myelodysplastic syndrome	Antibody	TIM3	TIM3 Antagonist	Mono	-
13	Immunology	Registration	INC424	Jakavi	ruxolitinib	Acute GVHD	Small molecules	JAK1/JAK2	JAK1/JAK2 inhibitor	Mono	Incyte Corp
14	Immunology	Registration	INC424	Jakavi	ruxolitinib	Chronic GVHD	Small molecules	JAK1/JAK2	JAK1/JAK2 inhibitor	Mono	Incyte Corp
15	Immunology	Phase 3	AIN457	Cosentyx	secukinumab	Giant cell arteritis	Antibody	IL17A	IL17A inhibitor	Mono	-
16	Immunology	Phase 3	AIN457	Cosentyx	secukinumab	Lupus Nephritis	Antibody	IL17A	IL17A inhibitor	Mono	-
17	Immunology	Phase 3	AIN457	Cosentyx	secukinumab	Hidradenitis suppurativa	Antibody	IL17A	IL17A inhibitor	Mono	-
18	Immunology	Phase 3	AIN457	Cosentyx	secukinumab	Psoriatic arthritis (IV formulation)	Antibody	IL17A	IL17A inhibitor	Mono	-
19	Immunology	Phase 3	AIN457	Cosentyx	secukinumab	Ankylosing spondylitis (IV formulation)	Antibody	IL17A	IL17A inhibitor	Mono	-
20	Immunology	Phase 3	LOU064		remibrutinib	Chronic spontaneous urticaria	Small molecules	BTK	BTK inhibitor	Mono	
21	Immunology	Phase 3	LOU064		remibrutinib	Multiple sclerosis	Small molecules	BTK	BTK inhibitor	Mono	
22	Immunology	Phase 3	VAY736		ianalumab	Lupus nephritis	Antibody	BAFF-R	BAFF-R inhibitor	Mono	
23	Immunology	Phase 2	AIN457	Cosentyx	secukinumab	Lichen Planus	Antibody	IL17A	IL17A inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
24	Immunology	Phase 2	CFZ533		iscalimab	Hidradenitis suppurativa	Antibody	CD40	CD40 inhibitor	Mono	-
25	Immunology	Phase 2	CFZ533		iscalimab	Liver Tx	Antibody	CD40	CD40 inhibitor	Mono	-
26	Immunology	Phase 2	CFZ533		iscalimab	Sjogren's syndrome	Antibody	CD40	CD40 inhibitor	Mono	-
27	Immunology	Phase 2	CMK389			Atopic dermatitis	Antibody	IL-18	IL-18 inhibitor	Mono	MorphoSys AG
28	Immunology	Phase 2	DFV890			Osteoarthritis	Small molecules	NLRP3	NLRP3 inhibitor	Mono	-
29	Immunology	Phase 2	DFV890			Familial cold auto-inflammatory syndrome	Small molecules	NLRP3	NLRP3 inhibitor	Mono	-
30	Immunology	Phase 2	INC424	Jakavi	ruxolitinib	Acute GVHD, Pediatrics	Small molecules	JAK1/JAK2	JAK1/JAK2 inhibitor	Mono	Incyte Corp
31	Immunology	Phase 2	INC424	Jakavi	ruxolitinib	Chronic GVHD, pediatrics	Small molecules	JAK1/JAK2	JAK1/JAK2 inhibitor	Mono	Incyte Corp
32	Immunology	Phase 2	LNA043			Osteoarthritis	Protein	ANGPTL3	ANGPTL3 Agonist	Combination	-
33	Immunology	Phase 2	LNA043			Knee osteoarthritis	Protein	ANGPTL3	ANGPTL3 Agonist	Mono	-
34	Immunology	Phase 2	LOU064		remibrutinib	Sjogren's syndrome	Small molecules	BTK	BTK inhibitor	Mono	-
35	Immunology	Phase 2	LRX712			Osteoarthritis	N/A	N/A	N/A	Mono	-
36	Immunology	Phase 2	LYS006			Hidradenitis suppurativa	Small molecules	N/A	Anti-inflammatory	Mono	-
37	Immunology	Phase 2	LYS006			Acne	Small molecules	N/A	Anti-inflammatory	Mono	-
38	Immunology	Phase 2	LYS006			Colitis ulcerative	Small molecules	N/A	Anti-inflammatory	Mono	-
39	Immunology	Phase 2	MAS825			NLRC4-GOF indications	N/A	Hepatitis A Virus Cellular Receptor 2	Hepatitis A Virus Cellular Receptor 2 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
40	Immunology	Phase 2	MAS825			Hidradenitis suppurativa	N/A	Hepatitis A Virus Cellular Receptor 2	Hepatitis A Virus Cellular Receptor 2 inhibitor	Mono	-
41	Immunology	Phase 2	MHV370			Sjorgen's syndrome	N/A	N/A	N/A	Mono	-
42	Immunology	Phase 2	MHV370			Mixed connective tissue disease	N/A	N/A	N/A	Mono	-
43	Immunology	Phase 2	VAY736		ianalumab	Sjogren's syndrome	Antibody	BAFF-R	BAFF-R inhibitor	Mono	-
44	Immunology	Phase 2	VAY736		ianalumab	Autoimmune hepatitis	Antibody	BAFF-R	BAFF-R inhibitor	Mono	-
45	Immunology	Phase 2	VAY736		ianalumab	Systemic lupus erythem atosus	Antibody	BAFF-R	BAFF-R inhibitor	Mono	-
46	Immunology	Phase 1	MHS552			Autoimmune Indications	N/A	N/A	N/A	Mono	-
47	Immunology	Phase 1	MHV370			Systemic lupus erythem atosus	N/A	N/A	N/A	Mono	-
48	Infectious	Registration	SKO136		ensovibep	Coronavirus infection	Protein	SARS-CoV-2 S	Multi-specific DARPin	Mono	-
49	Infectious	Phase 3	COA566	Coartem	artemether+ lumefantrine	Malaria uncomplicated (<5kg patients)	Small molecules	beta-Hematin	beta-Hematin inhibitor	Mono	Medicines for Malaria Venture
50	Infectious	Phase 2	KAE609		cipargamin	Malaria uncomplicated	Small molecules	PfATP4	PfATP4 inhibitor	Mono	-
51	Infectious	Phase 2	KAE609		cipargamin	Malaria severe	Small molecules	PfATP4	PfATP4 inhibitor	Mono	-
52	Infectious	Phase 2	KAF156		ganaplacide	Malaria uncomplicated	Small molecules	N/A	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
53	Infectious	Phase 2	LXE408			Visceral leishmaniosis	Small molecules	Proteasome	Proteasome inhibitor	Mono	-
54	Infectious	Phase 1	EYU688			Dengue	N/A	NS4B	NS4B inhibitor	Mono	-
55	Infectious	Phase 1	INE963			Malaria, uncomplicated	Small molecules	N/A	N/A	Mono	-
56	Infectious	Phase 1	KAF156		ganaplacide	Malaria prophylaxis	Small molecules	N/A	N/A	Mono	-
57	Metabolic	Phase 2	CFZ533		iscalimab	Type 1 Diabetes melitus	Antibody	CD40	CD40 inhibitor	Mono	-
58	Metabolic	Phase 2	LJN452		tropifexor + licogliflozin	NASH	Small molecules	FXR	FXR agonist	Mono	-
59	Metabolic	Phase 2	MBL949			Obesity related diseases	N/A	N/A	N/A	Mono	-
60	Metabolic	Phase 1	FIA586			NASH	N/A	N/A	N/A	Mono	-
61	Musculoskeletal	Phase 1	NGI226			Tendinopathy	N/A	N/A	N/A	Mono	-
62	Neuroscience	Phase 3	AMG334	Aimovig	erenumab-aooe	Migraine, pediatrics	Antibody	CGRP	Selective CGRP receptor antagonist	Mono	Amgen
63	Neuroscience	Phase 3	BAF312	Mayzent	siponimod	Multiple Sclerosis, pediatrics	Small molecules	S1P1	S1P1 Modulator	Mono	-
64	Neuroscience	Phase 3	OAV101			Spinal Muscular Atrophy IT administration	Gene therapy	Survival motor neuron (SMN1)	SMN1 activator	Mono	RegenxBio Inc
65	Neuroscience	Phase 3	OMB157	Kesimpta	subcutaneous ofatumumab	Multiple sclerosis, pediatrics	Antibody	CD20	CD20 Antagonist	Mono	Genmab
66	Neuroscience	Phase 2	ADPT06			Cognitive impairment	N/A	N/A	N/A	Mono	-
67	Neuroscience	Phase 2	BLZ945		sotuletinib	Amyotrophic Lateral Sclerosis	N/A	CSF-1R	CSF-1R inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
68	Neuroscience	Phase 2	DLX313			Parkinson's disease	Antibody	Alpha-synuclein	Alpha-synuclein Inhibitor	Mono	-
69	Neuroscience	Phase 2	LMI070		branaplam	Huntington's disease	Small molecules	Survival motor neuron (SMN2)	SMN2 RNA splicing modulator	Mono	-
70	Neuroscience	Phase 2	MIJ821			Major Depressive Disorder with acute suicidal ideation or behavior	Small molecules	NR2B	NR2B negative allosteric modulator	Mono	Cadent Therapeutics
71	Neuroscience	Phase 1	NIO752			Progressive Supranuclear Palsy	RNA	Tau	Antisense therapy	Mono	-
72	Oncology	Registration	CTL019	Kymriah	tisagenlecleucel	Relapsed/refractory Follicular Lymphoma	Cell Therapy	CD19	CD19 CAR-T	Mono	-
73	Oncology	Registration	VDT482		tislelizumab	2L ESCC Solid Tumors	Antibody	PD1	PD1 antagonist	Mono	Beigene
74	Oncology	Registration	VDT482		tislelizumab	Non-small cell lung cancer (NSCLC)	Antibody	PD1	PD1 antagonist	Mono	Beigene
75	Oncology	Phase 3	AAA601	Lutathera	lutetium Lu 177 dotatate	Gastroenteropancreatic neuroendocrine tumors, 1L in G2/3 tumors	Peptide	Somatostatin receptor	Radioligand therapy target	Mono	-
76	Oncology	Phase 3	AAA617	Pluvicto	lutetium Lu 177 vipivotide tetraxetan	Metastatic hormone sensitive prostate cancer	Other	PSMA	Radioligand therapy target PSMA	Mono	-
77	Oncology	Phase 3	AAA617	Pluvicto	lutetium Lu 177 vipivotide tetraxetan	Metastatic castration-resistant prostate cancer pre-taxane	Other	PSMA	Radioligand therapy target PSMA	Mono	-
78	Oncology	Phase 3	ABL001	Scemblix	asciminib	1L Chronic Myeloid Leukemia	Small molecules	BCR-ABL	BCR-ABL inhibitor	Mono	-
79	Oncology	Phase 3	ACZ885		canakinumab	Adjuvant NSCLC	Antibody	IL-1b	IL17A inhibitor	Mono	Bristol Myers Squibb Co.

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
80	Oncology	Phase 3	BYL719	Piqray	alpelisib	HER2+ advanced breast cancer	Small molecules	P13K-alpha	P13K-alpha inhibitor	Mono	-
81	Oncology	Phase 3	BYL719	Piqray	alpelisib	Ovarian cancer	Small molecules	P13K-alpha	P13K-alpha inhibitor	Mono	-
82	Oncology	Phase 3	BYL719	Piqray	alpelisib	TNBC	Small molecules	P13K-alpha	P13K-alpha inhibitor	Mono	-
83	Oncology	Phase 3	CTL019	Kymriah	tisagenlecleucel	1L high risk Acute Lymphocytic Leukemia, pediatrics and young adults	Cell Therapy	CD19	CD19 CAR-T	Mono	-
84	Oncology	Phase 3	DRB436	tafinlar® + mekinist®	dabrafenib+ trametinib	Thyroid cancer	Small molecules	BRAF, MEK	BRAF inhibitor + MEK inhibitor	Combination	-
85	Oncology	Phase 3	ETB115	Promacta	eltrombopag	Radiation sickness syndrome	Small molecules	Thrombopoietin	Thrombopoietin receptor (TPO-R) Agonist	Mono	Ligand Pharmaceuticals Inc
86	Oncology	Phase 3	INC280	Tabrecta	capmatinib	NSCLC	Small molecules	MET	MET inhibitor	Mono	Incyte Corp
87	Oncology	Phase 3	INC280	Tabrecta	capmatinib	NSCLC	Small molecules	MET	MET inhibitor	Combination	Incyte Corp
88	Oncology	Phase 3	JDQ443			2/3L NSCLC	Small molecules	KRAS	KRAS inhibitor	Mono	-
89	Oncology	Phase 3	LEE011	Kisqali	subcutaneous ofatumumab	Hormone receptor-positive, HER2-negative breast cancer (HR+, HER2- BC) (adjuvant)	Small molecules	CDK4/6	CDK4/6 inhibitor	Mono	-
90	Oncology	Phase 3	MBG453		sabatolimab	Myelodysplastic syndrome	Antibody	TIM3	TIM3 Antagonist	Mono	-
91	Oncology	Phase 3	NIS793			1L Metastatic pancreatic ductal adenocarcinoma	Antibody	TGFB1	TGFB1 inhibitor	Mono	Xoma
92	Oncology	Phase 3	VDT482		tislelizumab	1L Small Cell Lung Cancer	Antibody	PD1	PD1 Inhibitor	Mono	Beigene

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
93	Oncology	Phase 3	VDT482		tislelizumab	Adj/Neo adj. NSCLC	Antibody	PD1	PD1 Inhibitor	Mono	Beigene
94	Oncology	Phase 3	VDT482		tislelizumab	1L Urothelial Cell Carcinoma	Antibody	PD1	PD1 Inhibitor	Mono	Beigene
95	Oncology	Phase 3	VDT482		tislelizumab	1L Nasopharyngeal Carcinoma	Antibody	PD1	PD1 Inhibitor	Mono	Beigene
96	Oncology	Phase 3	VDT482		tislelizumab	1L Hepatocellular Carcinoma	Antibody	PD1	PD1 Inhibitor	Mono	Beigene
97	Oncology	Phase 3	VDT482		tislelizumab	1L Gastric cancer	Antibody	PD1	PD1 Inhibitor	Mono	Beigene
98	Oncology	Phase 3	VDT482		tislelizumab	1L ESCC	Antibody	PD1	PD1 Inhibitor	Mono	Beigene
99	Oncology	Phase 3	VDT482		tislelizumab	Localized ESCC	Antibody	PD1	PD1 Inhibitor	Mono	Beigene
100	Oncology	Phase 3	YTB323			2L Diffuse Large B-cell Lymphoma	Cell Therapy	CD19	CD19 CAR-T	Mono	-
101	Oncology	Phase 2	AAA601	Lutathera	lutetium Lu 177 dotatate	GEPNET, pediatrics	Peptide	Somatostatin receptor	Radioligand therapy target	Mono	-
102	Oncology	Phase 2	AAA601	Lutathera	lutetium Lu 177 dotatate	Glioblastoma	Peptide	Somatostatin receptor	Radioligand therapy target	Mono	-
103	Oncology	Phase 2	AAA601	Lutathera	lutetium Lu 177 dotatate	1L ES-SCLC	Peptide	Somatostatin receptor	Radioligand therapy target	Mono	-
104	Oncology	Phase 2	ABL001	Scemblix	asciminib	2L Chronic Myeloid Leukemia, pediatrics	Small molecules	BCR-ABL	BCR-ABL inhibitor	Mono	-
105	Oncology	Phase 2	BLZ945		sotuletinib	Solid tumors	N/A	CSF-1R	CSF-1R inhibitor	Mono	-
106	Oncology	Phase 2	DRB436	tafinlar® + mekinist®	dabrafenib+ trametinib	HGG/LGG, pediatrics	Small molecules	BRAF, MEK	BRAF inhibitor + MEK inhibitor	Combination	-
107	Oncology	Phase 2	JDQ443			NSCLC	Small molecules	KRAS	KRAS inhibitor	Combination	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
108	Oncology	Phase 2	MBG453		sabatolimab	Acute Myeloid Leukaemia, maintenance	Antibody	TIM3	TIM3 Antagonist	Mono	-
109	Oncology	Phase 2	MBG453		sabatolimab	Unfit Acute Myeloid Leukemia	Antibody	TIM3	TIM3 Antagonist	Mono	-
110	Oncology	Phase 2	NIR178		spartalizumab	Cancers	Small molecules	Ad2AR, PD1	Ad2AR Inhibitor, PD1 Inhibitor	Mono	Palobiofar ma S.L.
111	Oncology	Phase 2	NIS793			Colorectal cancer	Antibody	TGFB1	TGFB1 inhibitor	Combination	Xoma
112	Oncology	Phase 2	PHE885			4L Multiple Myeloma	Cell Therapy	BCMA	BCMA cell therapy	Mono	-
113	Oncology	Phase 2	PKC412	Rydapt	midostaurin	Acute Myeloid Leukemia, pediatrics	Small molecules	CD135, CD117	Multi-targeted kinase inhibitor	Mono	-
114	Oncology	Phase 2	TNO155			Solid tumors (single agent)	Small molecules	SHP2	SHP2 inhibitor	Mono	-
115	Oncology	Phase 1	AAA603		177Lu-NeoB	Multiple solid tumors	Peptide	GRPR	Radioligand therapy target GRPR	Mono	-
116	Oncology	Phase 1	AAA817		Ac-PSMA-617	Metastatic castration-resistant prostate cancer	Small molecules	PSMA	Radioligand therapy target PSMA	Mono	-
117	Oncology	Phase 1	ADPT01			Colorectal Cancer	Antibody	LAG3	LAG3 Inhibitor	Combination	-
118	Oncology	Phase 1	DFF332			Renal cell carcinoma	Small molecules	HIF2A	HIF2A inhibitor	Mono	-
119	Oncology	Phase 1	DKY709		DKY709 + spartalizumab	Cancers	N/A	Zinc Finger Protein Helios	Zinc Finger Protein Helios inhibitor	Combination	-
120	Oncology	Phase 1	HDM201		HDM201 + MBG453, venetoclax	Hematological malignancy	Small molecules	MDM2	MDM2 inhibitor	Combination	-
121	Oncology	Phase 1	IAG933			Mesothelioma	N/A	N/A	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
122	Oncology	Phase 1	JBH492			Hematological malignancy	ADC	CCR7	CCR7	Mono	-
123	Oncology	Phase 1	JDQ443			KRAS G12C mutated solid tumors	Small molecules	KRAS	KRAS inhibitor	Mono	-
124	Oncology	Phase 1	JEZ567			Acute Myeloid Leukemia	Cell Therapy	CD123	CD123 CAR-T	Mono	-
125	Oncology	Phase 1	KAZ954			Solid tumors	N/A	N/A	N/A	Mono	-
126	Oncology	Phase 1	MAK683			Cancers	Small molecules	EED	EED inhibitor	Mono	-
127	Oncology	Phase 1	MIK665			Acute Myeloid Leukemia	Small molecules	MCL1	MCL1	Combination	-
128	Oncology	Phase 1	NIS793		NIS793 + spartalizumab	1L metastatic colorectal cancer	Antibody	TGFB1	TGFB1 inhibitor	Combination	Xoma
129	Oncology	Phase 1	NIZ985		NIZ985 + spartalizumab	Solid tumors	Protein	IL-15	IL-15 Agonist	Combination	Xoma
130	Oncology	Phase 1	NZV930		NZV930 + spartalizumab + NIR178	Solid tumors	Antibody	CD73	CD73 Antagonist	Combination	Xoma
131	Oncology	Phase 1	PDR001		spartalizumab	Solid tumors	Antibody	PD1	PD1 Inhibitor	Combination	-
132	Oncology	Phase 1	TNO155			Solid tumors (combo)	Small molecules	SHP2	SHP2 inhibitor	Combination	-
133	Oncology	Phase 1	VAY736		ianalumab + ibrutinib	Hematological malignancy	Antibody	BAFF-R	BAFF-R inhibitor	Combination	-
134	Oncology	Phase 1	VOB560			Cancers	Small molecules	BCL2	BCL2	Mono	-
135	Oncology	Phase 1	VPM087		gevokizumab	1st line Colorectal Cancer	Antibody	IL-1B	IL-1B inhibitor	Mono	Xoma

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
136	Oncology	Phase 1	WNT974		WNT974 + spartalizumab	Solid tumors	Small molecules	Porcupine	Porcupine inhibitor	Mono	-
137	Oncology	Phase 1	WVT078			Multiple Myeloma	N/A	N/A	N/A	Mono	-
138	Oncology	Phase 1	YTB323			Diffuse Large B-cell Lymphoma and adult Acute Lymphocytic Leukemia	Cell Therapy	CD19	CD19 CAR-T	Mono	-
139	Ophthalmology	Phase 3	RTH258	Beovu	brolocizumab	Diabetic Retinopathy	Antibody	VEGF	VEGF inhibitor	Mono	-
140	Ophthalmology	Phase 2	CPK850			Retinitis pigmentosa	Gene therapy	RLBP1	RLBP1 activator	Mono	-
141	Ophthalmology	Phase 2	LKA651			Diabetic retinopathy	Antibody	EPO	EPO inhibitor	Mono	-
142	Ophthalmology	Phase 2	PPY988			Geographic atrophy	Gene therapy	N/A	N/A	Mono	N/A
143	Ophthalmology	Phase 2	SAF312		libvatrep	Chronic ocular surface pain	Small molecules	TRPV1	TRPV1 antagonist	Mono	-
144	Ophthalmology	Phase 2	UNR844			Presbyopia	Small molecules	N/A	N/A	Mono	-
145	Ophthalmology	Phase 1	MHU650			Diabetic eye diseases	N/A	N/A	N/A	Mono	-
146	Renal	Phase 3	LNP023		iptacopan	C3 glomerulopathy	Small molecules	Complement factor B (CFB)	CFB inhibitor	Mono	-
147	Renal	Phase 3	LNP023		iptacopan	IgA nephropathy	Small molecules	Complement factor B (CFB)	CFB inhibitor	Mono	-
148	Renal	Phase 2	LNP023		iptacopan	Membranous nephropathy	Small molecules	Complement factor B (CFB)	CFB inhibitor	Mono	-
149	Renal	Phase 2	CFZ533		iscalimab	Lupus nephritis	Antibody	CD40	CD40 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
150	Respiratory & Allergy	Phase 3	IGE025	Xolair	omalizumab	Auto-injector	Antibody	IgE	IgE Inhibitor	Mono	Genentech
151	Respiratory & Allergy	Phase 3	IGE025	Xolair	omalizumab	Food allergy	Antibody	IgE	IgE Inhibitor	Mono	Genentech
152	Respiratory & Allergy	Phase 3	QGE031		ligelizumab	Food allergy	Antibody	IgE	IgE Inhibitor	Mono	-
153	Respiratory & Allergy	Phase 2	CMK389			Pulmonary sarcoidosis	Antibody	IL-18	IL-18 inhibitor	Mono	MorphoSys AG
154	Respiratory & Allergy	Phase 2	CSJ117		ecleralimab	Asthma	Antibody	TSLP	TSLP inhibitor	Mono	MorphoSys AG
155	Respiratory & Allergy	Phase 2	CSJ117		ecleralimab	Asthma	Antibody	TSLP	TSLP inhibitor	Mono	MorphoSys AG
156	Respiratory & Allergy	Phase 2	QBW251		icenticaftor	Bronchiectasis	Small molecules	CFTR	CFTR Potentiator	Mono	-
157	Respiratory & Allergy	Phase 2	QBW251		icenticaftor	Chronic obstructive pulmonary disease	Small molecules	CFTR	CFTR Potentiator	Mono	-
158	Respiratory & Allergy	Phase 2	QMF149	Ateectura	indacaterol + mometasone furoate	Asthma, pediatrics	Small molecules	ADRB2, corticosteroid	ADRB2 Agonist; Glucocorticoid Receptor Agonist	Mono	-
159	Respiratory & Allergy	Phase 1	LTP001			Respiratory diseases	N/A	N/A	N/A	Mono	-
160	Respiratory & Allergy	Phase 1	NCJ424			Respiratory diseases	N/A	N/A	N/A	Mono	-

자료: Novartis 홈페이지, BioCentury, GlobalData